Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
Phase 1
Completed
- Conditions
- Body Weight Changes
- Registration Number
- NCT03509545
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Brief Summary
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
- Detailed Description
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
- Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.
Exclusion Criteria
- Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method change in 24-hour sodium excretion compared to baseline 24 hours the difference in 24 hour sodium excretion between ER Torsemide and Furosemide
- Secondary Outcome Measures
Name Time Method Changes in body weight 2 weeks Body weight changes will be compared between the two arms
Trial Locations
- Locations (1)
Syngene International
🇮🇳Bangalore, Karnataka, India